Citius Pharmaceuticals (CTXR) Competitors $1.64 -0.04 (-2.14%) As of 11:05 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. KLRS, IMMX, IZTC, ASRT, EQ, UNCY, VXRT, XBIT, RPTX, and COEPShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Kalaris Therapeutics (KLRS), Immix Biopharma (IMMX), Invizyne Technologies (IZTC), Assertio (ASRT), Equillium (EQ), Unicycive Therapeutics (UNCY), Vaxart (VXRT), XBiotech (XBIT), Repare Therapeutics (RPTX), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors Kalaris Therapeutics Immix Biopharma Invizyne Technologies Assertio Equillium Unicycive Therapeutics Vaxart XBiotech Repare Therapeutics Coeptis Therapeutics Citius Pharmaceuticals (NASDAQ:CTXR) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Do insiders & institutionals believe in CTXR or KLRS? 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CTXR or KLRS more profitable? Citius Pharmaceuticals' return on equity of -60.03% beat Kalaris Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Citius PharmaceuticalsN/A -60.03% -33.83% Kalaris Therapeutics N/A -81.02%-65.15% Which has more risk and volatility, CTXR or KLRS? Citius Pharmaceuticals has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500. Do analysts prefer CTXR or KLRS? Citius Pharmaceuticals presently has a consensus price target of $53.00, indicating a potential upside of 3,141.59%. Kalaris Therapeutics has a consensus price target of $3.00, indicating a potential downside of 33.63%. Given Citius Pharmaceuticals' higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than Kalaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Citius Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.33 Which has better valuation & earnings, CTXR or KLRS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCitius PharmaceuticalsN/AN/A-$39.14MN/AN/AKalaris TherapeuticsN/AN/A-$58.77MN/AN/A Does the media refer more to CTXR or KLRS? In the previous week, Citius Pharmaceuticals had 6 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 6 mentions for Citius Pharmaceuticals and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.67 beat Citius Pharmaceuticals' score of 0.43 indicating that Kalaris Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Citius Pharmaceuticals Neutral Kalaris Therapeutics Positive SummaryCitius Pharmaceuticals beats Kalaris Therapeutics on 7 of the 12 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.82M$2.97B$6.21B$10.63BDividend YieldN/A57.79%5.74%4.88%P/E RatioN/A23.6529.0727.24Price / SalesN/A776.79581.06183.55Price / CashN/A171.3937.5161.65Price / Book0.165.4012.256.56Net Income-$39.14M$33.06M$3.32B$276.14M7 Day Performance17.63%-1.83%0.19%-1.08%1 Month Performance40.95%6.67%6.61%1.88%1 Year Performance-82.28%-3.02%61.48%32.92% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.8056 of 5 stars$1.64-2.7%$53.00+3,141.6%-82.5%$27.82MN/A0.0020News CoverageGap DownKLRSKalaris Therapeutics1.2952 of 5 stars$4.76+7.0%$3.00-37.0%N/A$83.23MN/A0.00110IMMXImmix Biopharma3.2648 of 5 stars$2.50flat$8.00+220.0%+98.8%$82.59MN/A-3.259IZTCInvizyne TechnologiesN/A$12.95-4.1%N/AN/A$80.96MN/A0.0029ASRTAssertio2.8792 of 5 stars$0.84+0.9%$2.38+182.0%-27.8%$80.36M$124.96M-1.8720Positive NewsEQEquillium0.4782 of 5 stars$1.28-4.5%$1.00-21.9%+23.2%$79.73M$41.10M-2.2940News CoverageShort Interest ↑UNCYUnicycive Therapeutics2.6846 of 5 stars$4.49+1.1%$57.00+1,169.5%+13.6%$78.42M$680K-1.099VXRTVaxart1.7628 of 5 stars$0.34-2.4%$2.00+489.6%-53.8%$77.66M$47.40M-1.26120XBITXBiotech1.809 of 5 stars$2.56+0.8%N/A-65.8%$77.44M$4.01M-2.78100News CoverageShort Interest ↓Gap UpRPTXRepare Therapeutics2.7794 of 5 stars$1.82+1.1%$4.50+147.3%-47.8%$77.33M$53.48M-0.71180COEPCoeptis Therapeutics0.9487 of 5 stars$15.55-1.0%N/A+238.1%$75.68MN/A-2.682News CoverageShort Interest ↑ Related Companies and Tools Related Companies KLRS Competitors IMMX Competitors IZTC Competitors ASRT Competitors EQ Competitors UNCY Competitors VXRT Competitors XBIT Competitors RPTX Competitors COEP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 10/22/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredTesla to LEAVE the car market?Elon Musk says November 6 could "affect the future of the world" Get ready for the biggest pivot in corpora...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
